VCEL logo

Vericel (VCEL) Company Overview

Profile

Full Name:

Vericel Corporation

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

February 4, 1997

Indexes:

Not included

Website:

http://vcel.com

Description:

Vericel Corporation is a leader in advanced cell therapy methods and specialized biopreparations for the sports medicine and severe burn treatment markets. The company was founded in 1989. The headquarters, research division, all commercial and manufacturing operations are carried out at one facility located in Cambridge, Massachusetts. The company's products, based on the principles of autologous cell therapy, include Epicel, which is a bio-material permanent skin substitute for treating patients with deep skin burns or full-thickness skin burns. The company is also developing MACI - a third-generation autologous chondrocyte implant and the personalized multicellular therapy drug ixmyelocel-T.

Key Details

Price

$49.50

Market Cap

$2.44 B(Mid cap)

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$197.52 M(+20.17% YoY)

Annual EPS

-$0.07(+80.00% YoY)

PE Ratio

707.14

Annual ROE

-1.52%

Annual Debt To Equity

0.00

Beta

1.20

Events Calendar

Earnings

Next earnings date:

May 8, 2025

Recent quarterly earnings:

Feb 27, 2025

Recent annual earnings:

Feb 27, 2025
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Oct 16, 2013

Analyst ratings

Recent major analysts updates

Feb 3, 25 Canaccord Genuity
Buy
Jan 15, 25 Stephens & Co.
Overweight
Jan 15, 25 HC Wainwright & Co.
Buy
Dec 18, 24 Truist Securities
Buy
Nov 26, 24 BTIG
Buy
Nov 19, 24 Canaccord Genuity
Buy
Nov 8, 24 HC Wainwright & Co.
Buy
Aug 27, 24 TD Cowen
Buy
Aug 9, 24 Canaccord Genuity
Buy
Aug 2, 24 Stephens & Co.
Overweight

Screeners with VCEL included

Growing Shares Outstanding
Mid cap stocks
US stocks
Stocks with high beta
Most recommended stocks
Earnings this week
Best performing stocks last 5 years
Stocks below analysts price target
Healthcare sector
All stocks

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Current Price

$49.50
VCEL price is $49.50

Price All-time High

$1410.00
VCEL price is currently -96.49% below its historical high of $1410.00

Price Analysts Target

$66.50
VCEL price is currently -25.56% lower than the consensus analysts' forecast

Price Most Recent Change

-5.26%
VCEL price was down -5.26% on Feb 27, 2025

Price YTD Change

-11.59%
VCEL price is down -11.59% since January 1st

Price 3-Year Change

+20.12%
VCEL price is up +20.12% over the past 3 years

Market cap

Market Cap

$2.44 B
VCEL market capitalization is $2.44 billion

Market Cap 3-Year Change

+26.23%
VCEL market capitalization is up +26.23% over the past 3 years

Market Cap All-time High

$3.14 B
VCEL market capitalization is currently -22.27% below its historical high of $3.14 billion

Market Cap Sector Rank

83.73%
VCEL market capitalization is higher than 83.73% of companies in Healthcare sector

Technical

Beta

1.20
VCEL beta is 1.20

200-day SMA

$50.23
VCEL price is currently -1.46% below its 200-day simple moving average

14-day RSI

28.82
VCEL 14-day relative strength index is 28.82

30-day Relative Volume

1.63
VCEL 30-day relative volume is 1.63

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Annual Revenue

$197.52 M
VCEL annual revenue is $197.52 million

Annual Revenue Analysts Estimate

$238.33 M
VCEL annual revenue is currently -17.13% lower than the consensus analysts' forecast

Annual Revenue 1-Year Change

+20.17%
VCEL annual revenue is up +20.17% year-on-year

Annual Revenue Sector Rank

64.59%
VCEL annual revenue is higher than 64.59% of companies in Healthcare sector

Profit

Annual Gross Profit

$135.58 M
VCEL annual gross profit is $135.58 million

Annual Gross Margin

68.64%
VCEL annual gross profit margin is 68.64%

Annual Operating Profit

-$6.46 M
VCEL annual operating income is -$6.46 million

Annual Operating Margin

-3.27%
VCEL annual operating profit margin is -3.27%

Annual Net Income

-$3.18 M
VCEL annual net profit is -$3.18 million

Annual Net Margin

-1.61%
VCEL annual net profit margin is -1.61%

EPS

Annual EPS

-$0.07
VCEL annual earnings per share is -$0.07

Annual EPS Analysts Estimate

$0.16
VCEL annual earnings per share is currently -143.75% lower than the consensus analysts' forecast

Annual EPS 1-Year Change

+80%
VCEL annual earnings per share is up +80% year-on-year

Annual EPS Sector Rank

82.47%
VCEL annual earnings per share is higher than 82.47% of companies in Healthcare sector

ROA & ROE

Annual ROA

-1.02%
VCEL annual return on assets is -1.02%

Annual ROE

-1.52%
VCEL annual return on equity is -1.52%

EBIT & EBITDA

Annual EBIT

-$1.77 M
VCEL annual earnings before interest & taxes is -$1.77 million

Annual EBITDA

$2.86 M
VCEL annual EBITDA is $2.86 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE Ratio

707.14
VCEL price to earnings ratio is 707.14

PE Ratio Sector Rank

98.95%
VCEL price to earnings ratio is higher than 98.95% of companies in Healthcare sector

PB Ratio

PB Ratio

9.49
VCEL price to book ratio is 9.49

PB Ratio Sector Rank

90.91%
VCEL price to book ratio is higher than 90.91% of companies in Healthcare sector

PS Ratio

PS Ratio

10.77
VCEL price to sales ratio is 10.77

PS Ratio Sector Rank

78.28%
VCEL price to sales ratio is higher than 78.28% of companies in Healthcare sector

Enterprise value

Enterprise Value

$2.49 B
VCEL enterprise value is $2.49 billion

Enterprise Value Sector Rank

83.92%
VCEL enterprise value is higher than 83.92% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

238.22
VCEL EV/EBITDA is 238.22

EV/EBITDA Sector Rank

99.12%
VCEL EV/EBITDA is higher than 99.12% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Annual Current Ratio

4.49
VCEL annual current ratio is 4.49

Annual Quick Ratio

4.21
VCEL annual quick ratio is 4.21

Leverage

Annual Debt To Equity

0.00
VCEL annual debt to equity ratio is 0.00

Annual Interest Coverage Ratio

-2.95
VCEL annual interest coverage ratio is -2.95

Risk & Stability

Piotroski F-Score

5
VCEL piotroski f-score is 5

Altman Z-Score

10.97
VCEL altman z-score is 10.97

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Annual Total Assets

$353.66 M
VCEL annual total assets is $353.66 million

Annual Non Current Assets

$148.03 M
VCEL annual long term assets is $148.03 million

Annual Current Assets

$205.63 M
VCEL annual total current assets is $205.63 million

Annual Cash & Cash Equivalents

$69.09 M
VCEL annual cash & cash equivalents is $69.09 million

Equity

Annual Book Value

$225.95 M
VCEL annual book value is $225.95 million

Annual Working Capital

$159.88 M
VCEL annual working capital is $159.88 million

Liabilities

Annual Total Liabilities

$127.70 M
VCEL annual total liabilities is $127.70 million

Annual Total Long Term Liabilities

$81.96 M
VCEL annual total long term liabilities is $81.96 million

Annual Current Liabilities

$45.75 M
VCEL annual total current liabilities is $45.75 million

Annual Accounts Payable

$22.35 M
VCEL annual accounts payable is $22.35 million

Debt

Annual Total Debt

$88.04 M
VCEL annual total debt is $88.04 million

Annual Total Debt 1-Year Change

+85.08%
VCEL annual total debt is up +85.08% year-on-year

Annual Long Term Debt

$81.86 M
VCEL annual long term debt is $81.86 million

Annual Short Term Debt

$6.19 M
VCEL annual short term debt is $6.19 million

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Total Expenses

$203.98 M
VCEL annual total expenses is $203.98 million

Annual Operating Expenses

$142.04 M
VCEL annual total operating expenses is $142.04 million

Annual Cost Of Goods Sold

$61.94 M
VCEL annual cost of goods sold is $61.94 million

Annual SGA

$121.00 M
VCEL annual SGA is $121.00 million

Annual D&A

$4.63 M
VCEL annual depreciation & amortization is $4.63 million

Annual Interest Expense

$600.00 K
VCEL annual interest expense is $600.00 thousand

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Annual CFO

$35.31 M
VCEL annual cash flow from operations is $35.31 million

Annual CFO 1-Year Change

+99.64%
VCEL annual cash flow from operations is up +99.64% year-on-year

Annual CFI

-$3.13 M
VCEL annual cash flow from investing activities is -$3.13 million

Annual CFI 1-Year Change

+91.36%
VCEL annual cash flow from investing activities is up +91.36% year-on-year

Annual CFF

$3.62 M
VCEL annual cash flow from financing activities is $3.62 million

Annual CFF 1-Year Change

+246.22%
VCEL annual cash flow from financing activities is up +246.22% year-on-year

Free CashFlow

Annual FCF

$7.80 M
VCEL annual free cash flow is $7.80 million

Annual FCF 1-Year Change

-22.72%
VCEL annual free cash flow is down -22.72% year-on-year

CAPEX

Annual CAPEX

$27.51 M
VCEL annual capital expenditures is $27.51 million

Annual CAPEX 1-Year Change

+262.2%
VCEL annual capital expenditures is up +262.2% year-on-year

Institutional Ownership

Similar stocks

Rapport Therapeutics (RAPP)
EWTX logo
Edgewise Therapeutics (EWTX)
SEM logo
Select Medical Holdings (SEM)
ARWR logo
Arrowhead Pharmaceuticals (ARWR)
MIRM logo
Mirum Pharmaceuticals (MIRM)
Metsera (MTSR)
TWST logo
Twist Bioscience (TWST)
NAMS logo
NewAmsterdam Pharma Company NV (NAMS)
MLTX logo
MoonLake Immunotherapeutics (MLTX)

FAQ

  • What is the ticker symbol for Vericel?
  • Does Vericel pay dividends?
  • What sector is Vericel in?
  • What industry is Vericel in?
  • What country is Vericel based in?
  • When did Vericel go public?
  • Is Vericel in the S&P 500?
  • Is Vericel in the NASDAQ 100?
  • Is Vericel in the Dow Jones?
  • When was Vericel's last earnings report?
  • When does Vericel report earnings?
  • Should I buy Vericel stock now?

What is the ticker symbol for Vericel?

The ticker symbol for Vericel is NASDAQ:VCEL

Does Vericel pay dividends?

No, Vericel does not pay dividends

What sector is Vericel in?

Vericel is in the Healthcare sector

What industry is Vericel in?

Vericel is in the Biotechnology industry

What country is Vericel based in?

Vericel is headquartered in United States

When did Vericel go public?

Vericel's initial public offering (IPO) was on February 4, 1997

Is Vericel in the S&P 500?

No, Vericel is not included in the S&P 500 index

Is Vericel in the NASDAQ 100?

No, Vericel is not included in the NASDAQ 100 index

Is Vericel in the Dow Jones?

No, Vericel is not included in the Dow Jones index

When was Vericel's last earnings report?

Vericel's most recent earnings report was on Feb 27, 2025

When does Vericel report earnings?

The next expected earnings date for Vericel is May 8, 2025

Should I buy Vericel stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions